Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Endoscopic Healing of Crohn's Disease Could Differ by Biologic Endoscopic Healing of Crohn's Disease Could Differ by Biologic
Infliximab biosimilar and adalimumab resulted in better endoscopic healing rates than either vedolizumab or ustekinumab in a post hoc pooled analysis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 3, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Industry Payments Linked With Rheumatologists' Prescribing Industry Payments Linked With Rheumatologists' Prescribing
For every $100 in food/beverage payments, the probability of prescribing increased from 1.5% to 14% for most drugs. The increase was particularly high for infliximab and rACTH.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 24, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn's Meta-Analysis Favors SubQ Infliximab Over Vedolizumab in Crohn's
Researchers evaluated results of seven major studies to compare efficacy and safety of the two agents in Crohn ' s disease and ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 23, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Johnson & Johnson Reports Q4 and Full-Year 2021 Results
New Brunswick, N.J. (January 25, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2021. “Our 2021 performance reflects continued strength across all segments of our business. Guided by Our Credo, I am honored to assume the role of CEO, leading our global teams in continuing our work to deliver life-changing solutions to consumers, patients, and health care providers” said Joaquin Duato, Chief Executive Officer. “Given our strong results, financial profile, and innovative pipeline we are well positioned for success in 2022 and beyond.” OVERALL FINANCIAL RESULTS ...
Source: Johnson and Johnson - January 25, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news

Proactive Infliximab Monitoring Best Sustains Disease Control Proactive Infliximab Monitoring Best Sustains Disease Control
Proactive therapeutic drug monitoring with maintenance infliximab proved more effective in sustaining disease control than did standard care in patients with immune-mediated inflammatory diseases.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 21, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Adding Infliximab to Immunoglobulin in COVID-Related MIS-C Appears Beneficial Adding Infliximab to Immunoglobulin in COVID-Related MIS-C Appears Beneficial
For multisystem inflammatory syndrome in children, initial therapy with intravenous immunoglobulin plus infliximab is associated with better outcomes than IVIG alone, according to new study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 22, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Infliximab Bests Second IVIG Infusion in Refractory Kawasaki Disease Infliximab Bests Second IVIG Infusion in Refractory Kawasaki Disease
In children with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease, infliximab was safe and more effective than a second IVIG infusion in resolving fever, decreasing hospital length of stay, and reducing the need for additional therapy, researchers say.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 9, 2021 Category: Intensive Care Tags: Pediatrics News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports Q3 2021 Results
New Brunswick, N.J. (October 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health,” said Alex Gorsky, Chairman and Chief Executive Officer. “In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, ...
Source: Johnson and Johnson - October 19, 2021 Category: Pharmaceuticals Tags: Financial Source Type: news

Early Infliximab Could Change the Course of Crohn's Disease Early Infliximab Could Change the Course of Crohn's Disease
Starting infliximab early after diagnosis boosts the chance of achieving endoscopic remission and reduces the development of stenosis over the next 2 years, report clinicians from Germany.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 27, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Seven countries in the Region to participate in WHO ’s Solidarity PLUS trial
WHO’s Solidarity PLUS trial enters new phase to test 3 new candidate drugs for COVID-19  Cairo, 25 August 2021 – Seven countries in WHO’s Eastern Mediterranean Region have enrolled to participate in the Solidarity PLUS clinical trial led by WHO. Solidarity PLUS will evaluate 3 potential drugs for the treatment of COVID-19 infections – artesunate, imatinib and infliximab – aiming to protect people from severe hospitalization and death because of COVID-19.  These drugs were selected by an independent panel of experts who assess all available evidence on all relevant therapeutics. The drugs have proven...
Source: WHO EMRO News - August 25, 2021 Category: Middle East Health Source Type: news

WHO-led trial is studying three anti-inflammatory drugs as potential COVID-19 treatments 
A trial led by the World Health Organization is testing three anti-inflammatory drugs - artesunate, imatinib and infliximab- as potential treatments for COVID-19. (Source: the Mail online | Health)
Source: the Mail online | Health - August 12, 2021 Category: Consumer Health News Source Type: news

Certain Biologics May Boost Infection Risk in Psoriasis Patients Certain Biologics May Boost Infection Risk in Psoriasis Patients
Psoriasis patients who are new users of infliximab and adalimumab appear to be at a greater risk of serious infection than those beginning therapy with etanercept, according to French researchers.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 2, 2021 Category: Infectious Diseases Tags: Dermatology News Source Type: news